Jeroen Elassaiss-Schaap is an experienced pharmacometrician. He started his own consultancy company in 2014, after holding the position senior principal scientist at Merck (MSD). At Merck, he contributed to the development of pembrolizumab, the first PD-1 antibody approved in the United States, with a complete PK-PD strategy going from preclinical to clinical and supported the program up to and including filing. Jeroen was employed by Schering-Plough and, since 2005, by Organon. He has contributed to clinical and preclinical projects at an approximate 50:50 ratio throughout the years.
Jeroen has received his PhD in medicine at the Leiden University Medical Center in collaboration with the Netherlands Institute for Brain Research on his electrophysiological research on the suprachiasmatic nucleus, the mammalian clock of daily rhythmicity.
Research interests are translational pharmacometrics, i.e. the modeling of animal PK-PD with the objective of forecasting or fortifying human PK-PD models, and the technical science behind pharmacometry, or in other words, how to optimally explore data and estimate models. Jeroen functions within Pharmacology as senior consultant for technical questions, supervisor for postdocs.
Jeroen contributes to lectures in the BioPharmaceutical curriculum with a guest lecture on the role of PK-PD in drug discovery and development, and a hands-on workshop on ‘Big data’ using R.
- twitter: @PD_value
- linkedin: linkedin.com/in/jeroenes
- Eigen bedrijf in modeling automatisering